Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis
Jia Yang, Yinglong Chen, Huanmei Jing, Chang Liu, Xiaoling Chen, Jiaju Chu, Liyun Chen, Shijie Tang, Fei Yu, Wancong Zhang, Satabdi Datta Choudhury · 2026
Read Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis by Jia Yang, Yinglong Chen, Huanmei Jing, Chang Liu, Xiaoling Chen, Jiaju Chu, Liyun Chen, Shijie Tang, Fei Yu, Wancong Zhang, Satabdi Datta Choudhury (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13263637.txt.
Description
Jia Yang and co-authors review a 2026 survey of mesenchymal stem cell therapy for type 2 diabetes. These versatile stem cells, found in tissues such as bone marrow and fat, can calm inflammation and release healing signals. The review examines how they might regenerate insulin-making beta cells and how their tiny secreted packages, exosomes, may steady blood sugar.
Standard drugs control sugar only temporarily and can bring side effects, while islet transplants face donor shortages. Stem cells offer a cheaper, more available option, and studies suggest combined benefits across beta-cell repair, immune modulation, and tissue healing. The authors warn that long-term clinical data are still lacking, so their conclusions are a starting reference, not firm guidance.
Catalog record
| CREATOR | Jia Yang, Yinglong Chen, Huanmei Jing, Chang Liu, Xiaoling Chen, Jiaju Chu, Liyun Chen, Shijie Tang, Fei Yu, Wancong Zhang, Satabdi Datta Choudhury |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62357 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |